Overview
UCB SA is a global biopharmaceutical company, based in Belgium, that focuses on discovering and developing innovative medicines and solutions for people living with severe diseases of the immune system or the central nervous system.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for UCB SA as of 30 June 2025 is 6,848.00 MM.
- The operating income for UCB SA as of 30 June 2025 is 1,216.00 MM.
- The net income for UCB SA as of 30 June 2025 is 1,332.00 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 6,848.00 | 1,216.00 | 1,332.00 |
2025-03-31 | 6,500.00 | 1,032.00 | 1,198.50 |
2024-12-31 | 6,152.00 | 848.00 | 1,065.00 |
2024-09-30 | 5,803.00 | 669.50 | 652.50 |
2024-06-30 | 5,454.00 | 491.00 | 240.00 |
2024-03-31 | 5,318.00 | 534.50 | 291.50 |
2023-12-31 | 5,182.00 | 578.00 | 343.00 |
2023-06-30 | 5,111.00 | 544.00 | 330.00 |
2023-03-31 | 5,279.00 | 571.50 | 374.00 |
2022-12-31 | 5,447.00 | 599.00 | 418.00 |
2022-06-30 | 5,854.00 | 1,099.00 | 886.00 |
2022-03-31 | 5,815.50 | 1,206.50 | 972.00 |
2021-12-31 | 5,777.00 | 1,314.00 | 1,058.00 |
2021-09-30 | 5,647.00 | 1,209.50 | 999.00 |
2021-06-30 | 5,517.00 | 1,105.00 | 940.00 |
2021-03-31 | 5,432.00 | 1,070.50 | 836.00 |
2020-12-31 | 5,347.00 | 1,036.00 | 732.00 |
2020-06-30 | |||
2020-03-31 |
Income Statement: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | 5.61 | 5.48 |
2024-09-30 | 3.43 | 3.35 |
2024-06-30 | 1.26 | 1.22 |
2024-03-31 | 1.54 | 1.49 |
2023-12-31 | 1.81 | 1.76 |
2023-06-30 | 1.74 | 1.69 |
2023-03-31 | 1.97 | 1.91 |
2022-12-31 | 2.20 | 2.14 |
2022-06-30 | 4.68 | 4.56 |
2022-03-31 | 5.14 | 5.01 |
2021-12-31 | 5.60 | 5.45 |
2021-09-30 | 5.29 | 5.15 |
2021-06-30 | 4.98 | 4.85 |
2021-03-31 | 4.42 | 4.31 |
2020-12-31 | 3.87 | 3.77 |
2020-06-30 | 3.95 | 3.76 |
2020-03-31 | 4.09 | 3.93 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for UCB SA as of 30 June 2025 is 1,576.00 MM.
- The cash from investing activities for UCB SA as of 30 June 2025 is 286.00 MM.
- The cash from financing activities for UCB SA as of 30 June 2025 is -691.00 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | 1,576.00 | 286.00 | -691.00 |
2025-03-31 | 1,409.00 | 284.00 | -754.50 |
2024-12-31 | 1,242.00 | 282.00 | -818.00 |
2024-09-30 | 1,065.50 | -27.50 | -697.00 |
2024-06-30 | 889.00 | -337.00 | -576.00 |
2024-03-31 | 825.00 | -388.50 | -442.00 |
2023-12-31 | 761.00 | -440.00 | -308.00 |
2023-06-30 | 975.00 | -479.00 | -513.00 |
2023-03-31 | 1,047.00 | -1,029.50 | -221.50 |
2022-12-31 | 1,119.00 | -1,580.00 | 70.00 |
2022-06-30 | 1,462.00 | -1,687.00 | 166.00 |
2022-03-31 | 1,507.50 | -1,087.00 | -476.50 |
2021-12-31 | 1,553.00 | -487.00 | -1,119.00 |
2021-09-30 | 1,370.50 | -472.00 | -1,131.50 |
2021-06-30 | 1,188.00 | -457.00 | -1,144.00 |
2021-03-31 | 1,134.50 | -1,342.50 | 16.50 |
2020-12-31 | 1,081.00 | -2,228.00 | 1,177.00 |
2020-06-30 | |||
2020-03-31 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/e for UCB SA as of 30 June 2025 is 29.78.
- The p/book for UCB SA as of 30 June 2025 is 3.16.
- The p/tbv for UCB SA as of 30 June 2025 is 65.40.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | 29.78 | 3.16 | 65.40 |
2025-03-31 | 29.33 | 3.11 | 64.40 |
2024-12-31 | 149.01 | 3.99 | -63.98 |
2024-09-30 | 127.55 | 3.42 | -54.76 |
2024-06-30 | 76.04 | 2.91 | -51.04 |
2024-03-31 | 63.34 | 2.42 | -42.52 |
2023-12-31 | 45.16 | 1.65 | -18.87 |
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-06-30 | |||
2022-03-31 | 19.39 | 2.45 | 379.92 |
2021-12-31 | 20.16 | 2.47 | -44.90 |
2021-09-30 | 18.82 | 2.31 | -41.92 |
2021-06-30 | 13.95 | 1.71 | -31.07 |
2021-03-31 | 15.70 | 1.71 | -31.10 |
2020-12-31 | 17.93 | 1.80 | -19.74 |
2020-06-30 | 17.65 | 1.85 | -9.45 |
2020-03-31 | 17.05 | 1.85 | -9.42 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for UCB SA as of 30 June 2025 is 0.04.
- The ebit (3y)/ev for UCB SA as of 30 June 2025 is 0.02.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | 0.04 | 0.02 |
2025-03-31 | 0.04 | 0.02 |
2024-12-31 | 0.01 | 0.01 |
2024-09-30 | 0.01 | 0.02 |
2024-06-30 | 0.02 | 0.02 |
2024-03-31 | 0.02 | 0.03 |
2023-12-31 | 0.03 | 0.05 |
2023-06-30 | 0.03 | 0.05 |
2023-03-31 | 0.03 | 0.05 |
2022-12-31 | 0.07 | 0.06 |
2022-06-30 | 0.08 | 0.07 |
2022-03-31 | 0.06 | 0.05 |
2021-12-31 | 0.05 | 0.05 |
2021-09-30 | 0.06 | 0.05 |
2021-06-30 | 0.07 | 0.07 |
2021-03-31 | 0.07 | 0.07 |
2020-12-31 | 0.06 | 0.07 |
2020-06-30 | 0.06 | 0.07 |
2020-03-31 | 0.06 | 0.07 |
Management Effectiveness
- The roa for UCB SA as of 30 June 2025 is 0.07.
- The roe for UCB SA as of 30 June 2025 is 0.12.
- The roic for UCB SA as of 30 June 2025 is 0.08.
- The croic for UCB SA as of 30 June 2025 is 0.05.
- The ocroic for UCB SA as of 30 June 2025 is 0.10.
Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
2025-06-30 | 0.07 | 0.12 | 0.08 | 0.05 | 0.10 |
2025-03-31 | 0.07 | 0.12 | 0.08 | 0.05 | 0.10 |
2024-12-31 | 0.02 | 0.03 | 0.02 | -0.00 | 0.07 |
2024-09-30 | 0.02 | 0.07 | 0.02 | -0.00 | 0.07 |
2024-06-30 | 0.02 | 0.04 | 0.03 | 0.00 | 0.06 |
2024-03-31 | 0.02 | 0.04 | 0.03 | 0.00 | 0.06 |
2023-12-31 | 0.02 | 0.04 | 0.03 | -0.00 | 0.08 |
2023-06-30 | 0.03 | 0.04 | 0.03 | -0.00 | 0.08 |
2023-03-31 | 0.03 | 0.04 | 0.03 | -0.02 | 0.09 |
2022-12-31 | 0.06 | 0.11 | 0.07 | -0.01 | 0.12 |
2022-06-30 | 0.08 | 0.12 | 0.08 | -0.01 | 0.13 |
2022-03-31 | 0.08 | 0.13 | 0.09 | -0.01 | 0.14 |
2021-12-31 | 0.07 | 0.15 | 0.10 | -0.01 | 0.12 |
2021-09-30 | 0.08 | 0.14 | 0.10 | -0.02 | 0.12 |
2021-06-30 | 0.07 | 0.13 | 0.10 | -0.04 | 0.12 |
2021-03-31 | 0.06 | 0.12 | 0.09 | -0.02 | 0.12 |
2020-12-31 | 0.07 | 0.10 | 0.07 | 0.00 | 0.11 |
2020-06-30 | 0.07 | 0.12 | 0.08 | -0.00 | 0.09 |
2020-03-31 | 0.07 | 0.12 | 0.08 | 0.00 | 0.09 |
Gross Margins
- The gross margin for UCB SA as of 30 June 2025 is 0.72.
- The net margin for UCB SA as of 30 June 2025 is 0.17.
- The operating margin for UCB SA as of 30 June 2025 is 0.14.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
2025-06-30 | 0.72 | 0.17 | 0.14 |
2025-03-31 | 0.72 | 0.17 | 0.14 |
2024-12-31 | 0.68 | 0.04 | 0.09 |
2024-09-30 | 0.68 | 0.04 | 0.09 |
2024-06-30 | 0.67 | 0.07 | 0.11 |
2024-03-31 | 0.67 | 0.07 | 0.11 |
2023-12-31 | 0.68 | 0.06 | 0.11 |
2023-06-30 | 0.69 | 0.06 | 0.11 |
2023-03-31 | 0.69 | 0.07 | 0.11 |
2022-12-31 | 0.73 | 0.15 | 0.19 |
2022-06-30 | 0.75 | 0.15 | 0.19 |
2022-03-31 | 0.75 | 0.17 | 0.21 |
2021-12-31 | 0.75 | 0.18 | 0.23 |
2021-09-30 | 0.75 | 0.18 | 0.21 |
2021-06-30 | 0.75 | 0.17 | 0.21 |
2021-03-31 | 0.75 | 0.15 | 0.21 |
2020-12-31 | 0.75 | 0.14 | 0.20 |
2020-06-30 | 0.74 | 0.14 | 0.22 |
2020-03-31 | 0.74 | 0.15 | 0.22 |
Identifiers and Descriptors
Central Index Key (CIK) |
Industry Groups
SIC 2834 - Pharmaceutical Preparations |